Trial Information

Summary: Androgen Deprivation and Localized Radiotherapy to Metastases in Patients with Oligometastatic Hormone - Sensitive Prostate Cancer

You have been asked to participate in this research study because you have prostate cancer that metastasized (spread beyond the prostate) to just a few areas (oligometastatic).  The purpose of this study is to look at the effects of treating prostate cancer with androgen deprivation (depriving the tumor cell of a necessary growth substance—androgen, specifically testosterone) and localized radiotherapy in terms of shrinking your tumor and delaying the progression (growth) of the cancer. This study will also test the use of a new type of radiation therapy called helical tomotherapy as part of the treatment. Total duration of androgen deprivation will be 36 weeks.  Radiation will be given daily for 2-6 weeks.  When your treatment is complete, you will be followed until your prostate cancer begins to grow.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 2:28:27 PM